609a - a recombinant immunoglobulin g4 (igg4) kappa monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (pd-1; pdcd1; cd279), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-pd-1 monoclonal antibody 609a targets, binds to and inhibits pd-1 and its downstream signaling pathways. This may restore immune function through the activation of t-cells and t-cell-mediated immune responses against tumor cells. Pd-1, a transmembrane protein in the immunoglobulin superfamily (igsf) expressed on t-cells, functions as an immune checkpoint that negatively regulates t-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (pd-l1) or 2 (pd-l2); it plays an important role in tumor evasion from host immunity.
Up to date info
Latest research - 609a
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 609a for any updates.